MYCOTHERAPY

 

Mycotherapy is the application of medicinal mushrooms with therapeutic properties,

or their derivatives, in human health.

Scientific research has proven that mycotherapy, the use of therapeutic medicinal mushrooms and their compounds are both effective and justified for various pathological conditions.

Mushrooms have been used medicinally for centuries by ancient civilisations as potent tonics and healing agents. However, it's only recently that numerous scientific studies have revealed their powerful anti-cancer and immunity-enhancing properties.

 

Furthermore, their non-toxicity, even in very high dosages, makes this a highly desirable therapeutic methodology, whether used autonomously or in co-operation with allopathic protocols.

Mycotherapy has many specific fields of application:

Antibiotic and Tonic

Many types of cancer and Chemotherapy side effects

Immunity (Covid-19)

Parasites

Stomach Ulcers

High blood pressure

High cholesterol

Alzheimer's Disease/Dementia

Asthma

Kidney disease

Liver disease

Heart and lung issues

Mycotherapy goes beyond easing symptoms. The aim is always to establish healing the physical cause of an illness. It can give hope once again to patients with lasting chronic diseases.

References: 

  • Lu H, Yang Y, Gad E, et al. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clin Cancer Res. 2011;17(21):6742-6753. 

  • Kariya Y, Inoue N, Kihara T, et al. Activation of human natural killer cells by the protein-bound polysaccharide PSK independently of interferon and interleukin 2. Immunol Lett. 1992;31(3):241-245.  

  • Fisher M, Yang LX. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res. 2002;22(3):1737-1754. 

  • Ogoshi K, Satou H, Isono K, et al. Immunotherapy for esophageal cancer. A randomized trial in combination with radiotherapy and radiochemotherapy. Cooperative Study Group for Esophageal Cancer in Japan. Am J Clin Oncol. 1995;18(3):216-222.  

  • Kidd PM. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev. 2000;5(1):4-27.  

  • Jung KW, Park S, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J Korean Med Sci. 2010;25(8):1113-1121. 

  • Choi JH, Kim YB, Lim HY, et al. 5-fluorouracil, mitomycin-C, and polysaccharide-K adjuvant chemoimmunotherapy for locally advanced gastric cancer: the prognostic significance of frequent perineural invasion. Hepatogastroenterology. 2007;54(73):290-297. 

  • Tanaka H, Muguruma K, Ohira M, et al. Impact of adjuvant immunochemotherapy using protein-bound polysaccharide-K on overall survival of patients with gastric cancer. Anticancer Res. 2012;32(8):3427-3433. 

  • Zhang M, Zhang Y, Zhang L, Tian Q. Mushroom polysaccharide lentinan for treating different types of cancers: A review of 12 years clinical studies in China. Prog Mol Biol Transl Sci. 2019;163:297-328. 

  • Ina K, Furuta R, Kataoka T, et al. Chemo-Immunotherapy Using Lentinan for the Treatment of Gastric Cancer and Liver Metastases. Med Sci (Basel). 2016;4(2):8.  

  • Oba K, Kobayashi M, Matsui T, et al. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer Res. 2009;29(7):2739-2745. 

  • Nakazato H, Koike A, Saji S, et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet. 1994;343(8906):1122-1126. 

  • Oba K, Teramukai S, Kobayashi M, et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother. 2007;56(6):905-911. 

  • Toge T, Yamaguchi Y. Protein-bound polysaccharide increases survival in resected gastric cancer cases stratified with a preoperative granulocyte and lymphocyte count. Oncol Rep. 2000;7(5):1157-1161. 

  • Akagi J, Baba H. PSK may suppress CD57(+) T cells to improve survival of advanced gastric cancer patients. Int J Clin Oncol. 2010;15(2):145-152. 

  • Yoshino S, Nishikawa K, Morita S, et al. Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701). Eur J Cancer. 2016;65:164-171. 

  • Yoshitani S, Takashima S. Efficacy of postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly patients with resected colorectal cancer. Cancer Biother Radiopharm. 2009;24(1):35-40. 

  • Sakai T, Yamashita Y, Maekawa T, et al. Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer. Cancer Biother Radiopharm. 2008;23(4):461-467. 

  • Sakamoto J, Morita S, Oba K, et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother. 2006;55(4):404-411. 

  • Bishop KS, Kao CH, Xu Y, et al. From 2000years of Ganoderma lucidum to recent developments in nutraceuticals. Phytochemistry. 2015;114:56-65. 

  • Jin X, Ruiz Bequerie J, Sze DM, Chan GC. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database Syst Rev. 2012;(6):6CD007731. 

  • Chen X, Hu ZP, Yang XX, et al. Monitoring of immune response to a herbal immune-modulator in patients with advanced colorectal cancer. Int Immunopharmacol. 2006;6(3):499-508. 

  • Oka S, Tanaka S, Yoshida S, et al. A water-soluble extract from culture medium of Ganoderma lucidum mycelia suppresses the development of colorectal adenomas. Hiroshima J Med Sci. 2010;59(1):1-6. 

  • Shigama K, Nakaya A, Wakame K, et al. Alleviating effect of active hexose correlated compound (AHCC) for anticancer drug-induced side effects in non-tumor-bearing mice. J Exp Ther Oncol. 2009;8(1):43-51. 

  • Matsui K, Uhara J, Satoi S, et al. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol. 2002;37(1):78-86. 

  • Niwa Y, Matsuura H, Murakami M, et al. Evidence that naturopathic therapy including Cordyceps prolongs survival of patients with hepatocellular carcinoma. Integr Cancer Ther. 2013;12(1):50-68. 

  • Hashida C, Hayashi K, Jie L, et al. [Quantities of agaritine in mushrooms (Agaricus bisporus) and the carcinogenicity of mushroom methanol extracts on the mouse bladder epithelium]. Nihon Koshu Eisei Zasshi. 1990;37(6):400-405. 

  • Mukai H, Watanabe T, Ando M, Katsumata N. An alternative medicine, Agaricus blazei, may have induced severe hepatic dysfunction in cancer patients. Jpn J Clin Oncol. 2006;36(12):808-810.  

  •  Lee JS, Hong EK.  Agaricus blazei Murill enhances doxorubicin-induced apoptosis in human hepatocellular carcinoma cells by NFκB-mediated increase of intracellular doxorubicin accumulation. Int J Oncol. 2011;38(2):401-408.

 

 

© LifeFlo 2019  Design by Strohacker Studio